key: cord-0845456-5bdjqdxx
authors: Cheng, Newman
title: Cerebral Venous Sinus Thrombosis After Pfizer-BioNTech COVID-19 (BNT162b2) Vaccination
date: 2021-09-17
journal: J Clin Neurol
DOI: 10.3988/jcn.2021.17.4.573
sha: f544f12be6969d558d2ac171ec2fad7d180b6145
doc_id: 845456
cord_uid: 5bdjqdxx

nan

ed to oral warfarin (international normalized ratio=2-3) since he remained neurologically stable. He was also started on levetiracetam at 500 mg bid with no recurrence of seizures.

To date, more than 4 million doses of the BNT162b2 vaccine have been administered in Singapore. The present case report is the first of a local case of CVST that is temporally associated with the vaccine. There is still insufficient evidence that the rate of CVST associated with COVID-19 vaccines is higher than the background CVST incidence of 1.32-1.57/100,000/year. 5, 6 As the world continues its vaccination efforts, the occurrence of CVST should be kept in mind as a possible significant side effect. However, in line with recommendations 7,8 from various major committees, its rarity suggests that the benefits of CO-VID-19 vaccines still outweigh their risks. Worldwide monitoring and data collection would be highly prudent as we continue to administer mRNA and other vaccines in efforts to end the pandemic.

Informed consent was obtained from the patient.

Data sharing not applicable to this article as no datasets were generated or analyzed during the study. 

Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination

US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination

SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia

Cerebral venous thrombosis: a comprehensive review

The incidence of cerebral venous thrombosis: a cross-sectional study

Cerebral venous sinus thrombosis incidence is higher than previously thought: a retrospective population-based study

COVID-19 vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets

Updated recommendations from the Advisory Committee on Immunization Practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients-United States

The author has no potential conflicts of interest to disclose.

None